Angiotensin II receptor blockers in dermatology: a narrative review

References

• Fountain JH, Lappin SL. Physiology, Renin Angiotensin System. 2021. Jul 22. In: StatPearls.
   Google Scholar
• Barreras A, Gurk-Turner C. Angiotensin II receptor blockers. Proc Bayl Univ Med Cent. 2003;16(1):123–126.
   PubMedGoogle Scholar
• Chen R, Suchard MA, Krumholz HM, et al. Comparative first-line effectiveness and safety of ACE (angiotensin-converting enzyme) inhibitors and angiotensin receptor blockers: a multinational cohort study. Hypertension. 2021;78(3):591–603.
   PubMed Web of Science ®Google Scholar
• Baccino D, Merlo G, Cozzani E, et al. Cutaneous effects of antihypertensive drugs. G Ital Dermatol Venereol. 2020;155(2):202–211.
   PubMed Web of Science ®Google Scholar
• Ranugha PSS, Betkerur JB. Antihypertensives in dermatology part II – cutaneous adverse reactions to antihypertensives. Indian J Dermatol Venereol Leprol. 2018;84(2):137–147.
   PubMed Web of Science ®Google Scholar
• Lo Y, Tsai TF. Angiotensin converting enzyme and angiotensin converting enzyme inhibitors in dermatology: a narrative review. Expert Rev Clin Pharmacol. 2022;15(1):33–42.
   PubMed Web of Science ®Google Scholar
• Lo Y, Lin LY, Tsai TF. Use of calcium channel blockers in dermatology: a narrative review. Expert Rev Clin Pharmacol. 2021;14(4):481–489.
   PubMed Web of Science ®Google Scholar
• Hao SY, Ren M, Yang C, et al. Activation of skin renin-angiotensin system in diabetic rats. Endocrine. 2011;39(3):242–250.
   PubMed Web of Science ®Google Scholar
• Kambayashi Y, Nagata K, Ichiki T, et al. Insulin and insulin-like growth factors induce expression of angiotensin type-2 receptor in vascular-smooth-muscle cells. Eur J Biochem. 1996;239(3):558–565.
   PubMedGoogle Scholar
• Suzuki Y, Ruiz-Ortega M, Lorenzo O, et al. Inflammation and angiotensin II. Int J Biochem Cell Biol. 2003;35(6):881–900.
   PubMed Web of Science ®Google Scholar
• Margolis DJ, Hoffstad O, Thom S, et al. The differential effect of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers with respect to foot ulcer and limb amputation in those with diabetes. Wound Repair Regen. 2010;18(5):445–451.
   PubMed Web of Science ®Google Scholar
• Abadir P, Hosseini S, Faghih M, et al. Topical reformulation of valsartan for treatment of chronic diabetic wounds. J Invest Dermatol. 2018;138(2):434–443.
   PubMed Web of Science ®Google Scholar
• Fox JD, Baquerizo-Nole KL, Macquhae F, et al. Statins may be associated with six-week diabetic foot ulcer healing. Wound Repair Regen. 2016;24(2):454–457.
   PubMed Web of Science ®Google Scholar
• Stuermer EK, Besser M, Terberger N, et al. Side effects of frequently used antihypertensive drugs on wound healing in vitro. Skin Pharmacol Physiol. 2019;32(3):162–172.
   PubMed Web of Science ®Google Scholar
• Imai N, Hashimoto T, Kihara M, et al. Roles for host and tumor angiotensin II type 1 receptor in tumor growth and tumor-associated angiogenesis. Lab Invest. 2007;87(2):189–198.
   PubMed Web of Science ®Google Scholar
• Otake AH, Mattar AL, Freitas HC, et al. Inhibition of angiotensin II receptor 1 limits tumor-associated angiogenesis and attenuates growth of murine melanoma. Cancer Chemother Pharmacol. 2010;66(1):79–87.
   PubMed Web of Science ®Google Scholar
• Olschewski DN, Hofschröer V, Nielsen N, et al. The angiotensin II type 1 receptor antagonist losartan affects NHE1-Dependent melanoma cell behavior. Cell Physiol Biochem. 2018;45(6):2560–2576.
   PubMedGoogle Scholar
• Stüwe L, Müller M, Fabian A, et al. pH dependence of melanoma cell migration: protons extruded by NHE1 dominate protons of the bulk solution. J Physiol. 2007;585(Pt 2):351–360.
   PubMed Web of Science ®Google Scholar
• Christian JB, Lapane KL, Hume AL, et al. Association of ACE inhibitors and angiotensin receptor blockers with keratinocyte cancer prevention in the randomized VATTC trial. J Natl Cancer Inst. 2008;100(17):1223–1232.
   PubMed Web of Science ®Google Scholar
• Moscarelli L, Zanazzi M, Mancini G, et al. Keratinocyte cancer prevention with ACE inhibitors, angiotensin receptor blockers or their combination in renal transplant recipients. Clin Nephrol. 2010;73(6):439–445.
   PubMed Web of Science ®Google Scholar
• Schmidt SA, Schmidt M, Mehnert F, et al. Use of antihypertensive drugs and risk of skin cancer. J Eur Acad Dermatol Venereol. 2015;29(8):1545–1554.
   PubMed Web of Science ®Google Scholar
• Yoon C, Yang HS, Jeon I, et al. Use of angiotensin-converting-enzyme inhibitors or angiotensin-receptor blockers and cancer risk: a meta-analysis of observational studies. CMAJ. 2011;183(14):E1073–1084.
   PubMed Web of Science ®Google Scholar
• Nardone B, Majewski S, Kim AS, et al. Melanoma and non-melanoma skin cancer associated with angiotensin-converting-enzyme inhibitors, angiotensin-receptor blockers and thiazides: a matched cohort study. Drug Saf. 2017;40(3):249–255.
   PubMed Web of Science ®Google Scholar
• Fritsch A, Loeckermann S, Kern JS, et al. A hypomorphic mouse model of dystrophic epidermolysis bullosa reveals mechanisms of disease and response to fibroblast therapy. J Clin Invest. 2008;118(5):1669–1679.
   PubMed Web of Science ®Google Scholar
• Nyström A, Thriene K, Mittapalli V, et al. Losartan ameliorates dystrophic epidermolysis bullosa and uncovers new disease mechanisms. EMBO Mol Med. 2015;7(9):1211–1228.
   PubMed Web of Science ®Google Scholar
• Inamadar AC. Losartan as disease modulating therapy for recessive dystrophic epidermolysis bullosa. Dermatol Ther. 2020;33(6):e14279.
   PubMed Web of Science ®Google Scholar
• Fardoun MM, Nassif J, Issa K, et al. Raynaud's phenomenon: a brief review of the underlying mechanisms. Front Pharmacol. 2016;7:438.
   PubMed Web of Science ®Google Scholar
• Matucci-Cerinic C, Nagaraja V, Prignano F, et al. The role of the dermatologist in Raynaud's phenomenon: a clinical challenge. J Eur Acad Dermatol Venereol. 2018;32(7):1120–1127.
   PubMed Web of Science ®Google Scholar
• Rustin MH, Almond NE, Beacham JA, et al. The effect of captopril on cutaneous blood flow in patients with primary Raynaud's phenomenon. Br J Dermatol. 1987;117(6):751–758.
   PubMed Web of Science ®Google Scholar
• Janini SD, Scott DG, Coppock JS, et al. Enalapril in Raynaud's phenomenon. J Clin Pharm Ther. 1988;13(2):145–150.
   PubMed Web of Science ®Google Scholar
• Stewart M, Morling JR. Oral vasodilators for primary Raynaud's phenomenon. Cochrane Database Syst Rev. 2012;2012(7):CD006687.
   PubMedGoogle Scholar
• Dziadzio M, Denton CP, Smith R, et al. Losartan therapy for Raynaud’s phenomenon and scleroderma: clinical and biochemical findings in a fifteen-week, randomized, parallel-group, controlled trial. Arthritis Rheum. 1999;42(12):2646–2655.
   PubMedGoogle Scholar
• Pancera P, Sansone S, Secchi S, et al. The effects of thromboxane A2 inhibition (picotamide) and angiotensin II receptor blockade (losartan) in primary Raynaud's phenomenon. J Intern Med. 1997;242(5):373–376.
   PubMed Web of Science ®Google Scholar
• Ghaedi F, Etesami I, Aryanian Z, et al. Drug-induced pemphigus: a systematic review of 170 patients. Int Immunopharmacol. 2021;92:107299.
   PubMed Web of Science ®Google Scholar
• Maruani A, Machet MC, Carlotti A, et al. Immunostaining with antibodies to desmoglein provides the diagnosis of drug-induced pemphigus and allows prediction of outcome. Am J Clin Pathol. 2008;130(3):369–374.
   PubMed Web of Science ®Google Scholar
• Pile HD, Yarrarapu SNS, Crane JS. Drug induced pemphigus. 2021. In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2021.
   Google Scholar
• Palleria C, Bennardo L, Dastoli S, et al. Angiotensin-converting-enzyme inhibitors and angiotensin II receptor blockers induced pemphigus: a case series and literature review. Dermatol Ther. 2019;32(1):e12748.
   PubMed Web of Science ®Google Scholar
• Bae YI, Yun SJ, Lee SC, et al. Pemphigus foliaceus induced by an angiotensin II receptor blocker. Clin Exp Dermatol. 2008;33(6):721–723.
   PubMed Web of Science ®Google Scholar
• Pietkiewicz P, Gornowicz-Porowska J, Bowszyc-Dmochowska M, et al. A retrospective study of antihypertensives in pemphigus: a still unchartered odyssey particularly between thiols, amides and phenols. Arch Med Sci. 2015;11(5):1021–1027.
   PubMed Web of Science ®Google Scholar
• Femiano F. Mucocutaneous bullous pemphigoid induced by valsartan. A clinical case. Minerva Stomatol. 2003;52(4):187–190.
   PubMedGoogle Scholar
• Bastuji-Garin S, Joly P, Picard-Dahan C, et al. Drugs associated with bullous pemphigoid. A case-control study. Arch Dermatol. 1996;132(3):272–276.
   PubMedGoogle Scholar
• Lloyd-Lavery A, Chi CC, Wojnarowska F, et al. The associations between bullous pemphigoid and drug use: a UK case-control study. JAMA Dermatol. 2013;149(1):58–62.
   PubMed Web of Science ®Google Scholar
• Azzouz B, Morel A, Kanagaratnam L, et al. Psoriasis after exposure to Angiotensin-Converting enzyme inhibitors: French pharmacovigilance data and review of the literature. Drug Saf. 2019;42(12):1507–1513.
   PubMed Web of Science ®Google Scholar
• Azzouz B, Abou Taam M, Morel A, et al. Psoriasis during angiotensin receptor blocker exposure: an underestimated adverse drug reaction. Expert Opin Drug Saf. 2018;17(9):853–857.
   PubMed Web of Science ®Google Scholar
• Marquart-Elbaz C, Grosshans E, Lipsker D, et al. Sartans, angiotensin II receptor antagonists, can induce psoriasis. Br J Dermatol. 2002;147(3):617–618.
   PubMed Web of Science ®Google Scholar
• Kawamura A, Ochiai T. Candesartan cilexetil induced pustular psoriasis. Eur J Dermatol. 2003;13(4):406–407.
   PubMed Web of Science ®Google Scholar
• Wolf R, Machtey I, Feverman EJ, et al. The kallikrein-kinin pathway in psoriasis. Preliminary observations. Biomedicine. 1981;35(3):77–78.
   PubMedGoogle Scholar
• Kim HN, Han K, Song SW, et al. Hypertension and risk of psoriasis incidence: an 11-year nationwide population-based cohort study. PLOS ONE. 2018;13(8):e0202854.
   PubMed Web of Science ®Google Scholar
• Vena GA, Cassano N, Coco V, et al. Eczematous reactions due to angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers. Immunopharmacol Immunotoxicol. 2013;35(3):447–450.
   PubMed Web of Science ®Google Scholar
• Ozturk G, Turk BG, Senturk B, et al. Exanthematous drug eruption due to valsartan. Cutan Ocul Toxicol. 2012;31(4):335–337.
   PubMed Web of Science ®Google Scholar
• Sawada Y, Yoshiki R, Kawakami C, et al. Valsartan-induced drug eruption followed by CD30+ pseudolymphomatous eruption. Acta Derm Venereol. 2010;90(5):521–522.
   PubMed Web of Science ®Google Scholar
• Viola E, Coggiola Pittoni A, Drahos A, et al. Photosensitivity with angiotensin II receptor blockers: a retrospective study using data from VigiBase(®). Drug Saf. 2015;38(10):889–894.
   PubMed Web of Science ®Google Scholar
• Gandini S, Palli D, Spadola G, et al. Anti-hypertensive drugs and skin cancer risk: a review of the literature and meta-analysis. Crit Rev Oncol Hematol. 2018;122:1–9.
   PubMed Web of Science ®Google Scholar
• Tchernev G, Patterson JW. Telmisartan/hydrochlorothiazide-induced nevus-associated cutaneous melanoma: first report in the medical literature. Expert Rev Clin Pharmacol. 2021;14(3):289–293.
   PubMed Web of Science ®Google Scholar
• Mold JW, Holtzclaw BJ. Selective serotonin reuptake inhibitors and night sweats in a primary care population. Drugs Real World Outcomes. 2015;2(1):29–33.
   PubMedGoogle Scholar
• Mirza FS, Ong P, Collins P, et al. Effects of estradiol and the angiotensin II receptor blocker irbesartan on vascular function in postmenopausal women. Menopause. 2008;15(1):44–50.
   PubMed Web of Science ®Google Scholar